2112-22-3

Usage

Uses

Used in Pharmaceutical Industry:
2,3-Dichloro-6-nitrobenzonitrile is used as an intermediate in the synthesis of anagrelide, a medication used to treat certain blood disorders, such as thrombocythemia.
Used in Chemical Synthesis:
2,3-Dichloro-6-nitrobenzonitrile is used as a starting reagent for the synthesis of ethyl (2-amino-5,6-dichlorobenzyl)glycinate, which can be further utilized in the development of various chemical compounds and pharmaceuticals.

InChI:InChI=1/C7H2Cl2N2O2/c8-5-1-2-6(11(12)13)4(3-10)7(5)9/h1-2H

Upstream product

• 75618-41-6 2,3-dichloro-6-nitro benzaldehyde 
• 17700-09-3 4-nitro-1,2,3-trichlorobenzene 
• 87-61-6 1,2,3-trichlorobenzene 
• 544-92-3 copper(I) cyanide 

Downstream Products

• 96336-87-7 2-chloro-6-nitro-3-pyrrolidinobenzonitrile 
• 97112-65-7 2-Chloro-6-nitro-3-piperidin-1-yl-benzonitrile 
• 97112-68-0 2-Chloro-3-(4-methyl-piperazin-1-yl)-6-nitro-benzonitrile 
• 97112-67-9 2-Chloro-3-(4-methyl-piperidin-1-yl)-6-nitro-benzonitrile 
• 97112-63-5 2-Chloro-3-dimethylamino-6-nitro-benzonitrile 
• 97112-64-6 2-Chloro-3-diethylamino-6-nitro-benzonitrile 
• 97112-66-8 2-Chloro-3-(2-methyl-piperidin-1-yl)-6-nitro-benzonitrile 
• 147249-41-0 2,3-dichloro-6-aminobenzonitrile 
• 147249-42-1 6-amino-2,3-dichlorobenzylamine 
• 97113-16-1 (3-Aminomethyl-2-chloro-4-nitro-phenyl)-dimethyl-amine 
• 97112-77-1 6-Amino-2-chloro-3-pyrrolidin-1-yl-benzonitrile 
• 97113-17-2 (3-Aminomethyl-2-chloro-4-nitro-phenyl)-diethyl-amine 
• 97112-78-2 6-Amino-2-chloro-3-piperidin-1-yl-benzonitrile 
• 96336-88-8 6-chloro-2-nitro-5-pyrrolidinobenzylamine 

Relevant academic research and scientific papers

METHOD FOR THE PRODUCTION OF ANAGRELIDE HYDROCHLORIDE

Disclosed is a method for producing 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazoline-2(3H)-on hydrochloride (anagrelide hydrochloride). Said method comprises the following steps: a) 2,3-dichlorobenzaldehyde is nitrated to obtain 2,3-dichloro-6-nitrobenzaldehyde; b) 2,3-dichloro-6-nitrobenzaldehyde is reacted with hydroxylamine HCl and acetic anhydride by applying heat so as to obtain 2,3-dichloro-6-nitrobenzonitrile; c) the nitro group of 2,3-dichloro-6-nitrobenzonitrile is reduced to obtain 2,3-dichloro-6-aminobenzonitrile; d) the nitrile group of 2,3-dichloro-6-aminobenzonitrile is reduced to obtain 2,3-dichloro-6-aminobenzylamine dihydrochloride; e) 2,3-dichloro-6-aminobenzylamine dihydrochloride is reacted with i) bromoacetic acid ethyl ester, CH3CN, and triethylamine; and ii) BrCN to obtain (2-amino-5,6-dichloro-4H-quinazoline-3-yl) acetic acid ethyl ester; f) (2-amino-5,6-dichloro-4H-quinazoline-3-yl) acetic acid ethyl ester is reacted in cycloalkylation conditions to obtain 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazoline-2(3H)-on; and g) 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazoline-2(3H)-on is reacted with HCl to obtain anagrelide hydrochloride.

2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof

The compound 2-amino-5,6-dichloro-3,4-dihydroquinazoline has been found to have enhanced platelet count reducing properties. Also provided are methods for synthetically making the compound and a method of reducing the platelet count in a patient by administering to the patient a platelet reducing effective amount of the compound preferably together with a pharmaceutically acceptable carrier. A pharmaceutical composition is also provided which contains the above compound as the active ingredient together with pharmaceutically acceptable excipients.

Alkyl 5,6-dichloro-3,4-dihydro-2(1H)-iminoquinazoline-3-acetate hydrohalides

The known blood platelet antiaggregative agent 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one is prepared in high yield via an improved process involving a novel intermediate of the Formula STR1 in which R1 is (lower)alkyl and X is bromo, chloro or iodo. Two processes for the preparation of compounds of the Formula III are disclosed, one of which involves the novel intermediate STR2